Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

• Published in: BMC medicine Vol. 20; no. 1; pp. 187 - 15
• Main Authors: Liu, Chengming, Yang, Lu, Xu, Haiyan, Zheng, Sufei, Wang, Zhanyu, Wang, Sihui, Yang, Yaning, Zhang, Shuyang, Feng, Xiaoli, Sun, Nan, Wang, Yan, He, Jie
• Format: Journal Article
• Language: English
• Published: England BioMed Central 13.05.2022; BMC
• Subjects: Animal models; Antibiotics; Biomarkers; Cancer therapies; CD8 antigen; Clinical response; Cloning; Cytokines; IL-6; Immune checkpoint inhibitors; Immunology; Immunotherapy; Inflammation; Interleukin 6; Janus kinase; Lung cancer; Lymphocytes; Lymphocytes T; Macrophages; Medical research; Melanoma; Metastases; Non-small cell lung carcinoma; NSCLC; Patients; PD-L1 protein; Phenotypes; Plasma; Resistance; Small cell lung carcinoma; Stat3 protein; Suppressor cells; Tumor necrosis factor-TNF; Tumors; United Kingdom > UK; United States > US; China; Resistance; Immune checkpoint inhibitors; NSCLC; Clinical response; IL-6
• DOI: 10.1186/s12916-022-02356-7
• ISSN: 1741-7015

Cytokines have been reported to alter the response to immune checkpoint inhibitors (ICIs) in patients with the tumor in accordance with their plasma concentrations. Here, we aimed to identify the key cytokines which influenced the responses and stimulated resistance to ICIs and tried to improve immunological response and develop novel clinical treatments in non-small cell lung cancer (NSCLC). The promising predictive cytokines were analyzed via the multi-analyte flow assay. Next, we explored the correlation baseline level of plasma cytokines and clinical outcomes in 45 NSCLC patients treated with ICIs. The mechanism of the potential candidate cytokine in predicting response and inducing resistance to ICIs was then investigated. We found NSCLC with a low baseline concentration of IL-6 in plasma specimens or tumor tissues could derive more benefit from ICIs based on the patient cohort. Further analyses revealed that a favorable relationship between PD-L1 and IL-6 expression was seen in NSCLC specimens. Results in vitro showed that PD-L1 expression in the tumor was enhanced by IL-6 via the JAK1/Stat3 pathway, which induced immune evasion. Notably, an adverse correlation was found between IL-6 levels and CD8 T cells. And a positive association between IL-6 levels and myeloid-derived suppressor cells, M2 macrophages and regulator T cells was also seen in tumor samples, which may result in an inferior response to ICIs. Results of murine models of NSCLC suggested that the dual blockade of IL-6 and PD-L1 attenuated tumor growth. Further analyses detected that the inhibitor of IL-6 stimulated the infiltration of CD8 T cells and yielded the inflammatory phenotype. This study elucidated the role of baseline IL-6 levels in predicting the responses and promoting resistance to immunotherapy in patients with NSCLC. Our results indicated that the treatment targeting IL-6 may be beneficial for ICIs in NSCLC.